Source: wutzkohphoto / Shutterstock.com Once a high-growth stock, Netflix (NASDAQ:NFLX) is going through a difficult period. After losing subscribers, it has a lot to work on. Consequently, NFLX stock has seen a massive dip over the past six months. The stock was once as high as $700 and is now down to $195. It lost
Month: June 2022
Source: Shutterstock Cannabis stocks have experienced significant growth in the past few months. However, this trend came to an end in the last few weeks when the stocks of many cannabis companies started to plummet. Unfortunately, HEXO (NASDAQ:HEXO) stock is not an exception in this regard. Following a string of unfortunate events, the Canadian cannabis
Source: Ralf Liebhold / Shutterstock.com ContextLogic (NASDAQ:WISH) is one of the most volatile stocks and has been falling consistently since its initial public offering (IPO). However, the stock has recently started going up. The price of WISH stock has gone up 24% in two weeks, and it looks like the stock is finally bottoming out.
Source: Shutterstock Before November 2021, most investors and pundits believed that the Street’s favorite large-cap tech stocks — including Facebook (NASDAQ:FB), Apple (NASDAQ:AAPL) and Tesla (NASDAQ:TSLA) — were mostly or completely immune from major downturns. As a result, many, if not most, institutional investors loaded up on these names and others like them. But now,
June is a good time to sell large-cap stocks that may not be able to create much shareholder value in the second half of the year. Coinbase Global (COIN): The crypto exchange is likely to stay volatile as digital assets decline further. Roblox (RBLX): Revenue growth is on the decline and Roblox has no definite path
Source: bacho / Shutterstock.com Equity market headwinds may dent flows into equities in the following quarters. Rising interest rates and ramping inflation should continue to weigh on world economic growth and bring additional downside on growth stocks. Since the beginning of the year, equity markets measured by the SPDR S&P 500 Trust ETF (NYSEARCA:SPY) dipped
Source: Postmodern Studio / Shutterstock.com New York-headquartered Teladoc Health (NYSE:TDOC) is a telemedicine specialist that seemed to offer great promise during 2020’s emergence of the Covid-19 pandemic. While TDOC stock did have its glory days, they’re in the rear-view mirror. As a result, it’s wise to avoid it now. Even if you believe in the future
These six sucker stocks may look like bargains right now, as they have all recently fallen quite dramatically. However, their underlying problems or simply the fact that they have apparent problems could wear away at their stock prices over the long term. In some cases, the stock may have issued a profit warning. And in
Equities research analysts predict that Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) will post earnings per share of ($0.67) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Kymera Therapeutics’ earnings, with estimates ranging from ($0.80) to ($0.58). Kymera Therapeutics posted earnings of ($0.55) per share in the same
Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership. Earnings and Valuation Get Nautilus Biotechnology
NeoGames (NASDAQ:NGMS – Get Rating) is one of 33 publicly-traded companies in the “Amusement & recreation services” industry, but how does it contrast to its peers? We will compare NeoGames to related businesses based on the strength of its earnings, dividends, risk, analyst recommendations, institutional ownership, profitability and valuation. Valuation and Earnings Get NeoGames alerts:
Brokerages expect ArcBest Co. (NASDAQ:ARCB – Get Rating) to report $3.86 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for ArcBest’s earnings, with estimates ranging from $3.67 to $4.06. ArcBest reported earnings per share of $1.97 during the same quarter last year, which would
Fujitsu (OTCMKTS:FJTSY – Get Rating) and Jungheinrich Aktiengesellschaft (OTCMKTS:JGHAF – Get Rating) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Analyst Recommendations Get Fujitsu alerts: This is a breakdown
Analysts expect that Amyris, Inc. (NASDAQ:AMRS – Get Rating) will post earnings per share of ($0.22) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Amyris’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.38). Amyris reported earnings of ($0.16) per share
Better Therapeutics (NASDAQ:BTTX – Get Rating) and Accelera Innovations (OTCMKTS:ACNV – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Risk and Volatility Get Better Therapeutics alerts: Better Therapeutics has
Analysts expect that CoreCivic, Inc. (NYSE:CXW – Get Rating) will report earnings per share (EPS) of $0.36 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for CoreCivic’s earnings, with estimates ranging from $0.33 to $0.38. CoreCivic reported earnings per share of $0.46 in the same quarter last year, which
Oatly Group (NASDAQ:OTLY – Get Rating) is one of 31 publicly-traded companies in the “Food & kindred products” industry, but how does it weigh in compared to its competitors? We will compare Oatly Group to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Profitability Get
Wall Street analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) to report earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aldeyra Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.36). Aldeyra Therapeutics
A shorter version of this article appeared in the April 25, 2017 issue of Forbes. It’s spring: Corporate proxies are in the mail. Are these a noble exercise in shareholder democracy? Or an expensive farce? If you own corporate shares directly, your mailbox will soon fill up with ballots for directors and auditors. Should you
Part of the financial center in Moscow. The equity markets took a slight hit on Wednesday following… [+] news that the EU would be extending its sectoral sanctions for the rest of the year…and then some. (Photo by Kenneth Rapoza/FORBES) Sorry Market Vectors Russia (RSX) ETF holders, the Russian sanctions we all hoped would be